TY  - BOOK
AU  - Baez, Valentina
AU  - Blumenthal, Joseph
AU  - Fernandez, Stephen J
AU  - Hettinger, Aaron Z
AU  - Shenoy, Aarthi G
TI  - Early mortality benefit with COVID-19 convalescent plasma: a matched control study
SN  - 0007-1048
PY  - 2021///
KW  - *COVID-19/th [Therapy]
KW  - *SARS-CoV-2/me [Metabolism]
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - COVID-19/bl [Blood]
KW  - COVID-19/mo [Mortality]
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Immunization, Passive
KW  - Male
KW  - Middle Aged
KW  - Retrospective Studies
KW  - Risk Factors
KW  - Survival Rate
KW  - Time Factors
KW  - MedStar Harbor Hospital
KW  - MedStar Heart & Vascular Institute
KW  - MedStar Institute for Innovation
KW  - MedStar Washington Hospital Center
KW  - Washington Cancer Institute
KW  - Emergency Medicine
KW  - Medicine
KW  - Journal Article
N1  - Available online through MWHC library: 1995 - 2013
N2  - Convalescent plasma can provide passive immunity during viral outbreaks, but the benefit is uncertain for the treatment of novel coronavirus disease 2019 (COVID-19). Our goal is to assess the efficacy of COVID-19 convalescent plasma (CCP). In all, 526 hospitalized patients with laboratory-confirmed SARS-CoV-2 at an academic health system were analyzed. Among them, 263 patients received CCP and were compared to 263 matched controls with standard treatment. The primary outcome was 28-day mortality with a subanalysis at 7 and 14 days. No statistical difference in 28-day mortality was seen in CCP cases (25.5%) compared to controls (27%, P = 0.06). Seven-day mortality was statistically better for CCP cases (9.1%) than controls (19.8%, P < 0.001) and continued at 14 days (14.8% vs. 23.6%, P = 0.01). After 72 h, CCP transfusion resulted in transitioning from nasal cannula to room air (median 4 days vs. 1 day, P = 0.02). The length of stay was longer in CCP cases than controls (14.3 days vs. 11.4 days, P < 0.001). Patients with COVID-19 who received CCP had a decreased risk of death at 7 and 14 days, but not 28 days after transfusion. To date, this is the largest study demonstrating a mortality benefit for the use of CCP in patients with COVID-19 compared to matched controls. Copyright (c) 2020 British Society for Haematology and John Wiley & Sons Ltd
UR  - https://dx.doi.org/10.1111/bjh.17272
ER  -